AYGESTIN

LOE Approaching

norethindrone acetate

NDAORALTABLET
Approved
Apr 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the…

Indications (1)

pregnancy in women

Clinical Trials (5)

NCT03271489Phase 3Completed

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Started Sep 2017
478 enrolled
Heavy Menstrual BleedingUterine Fibroids
NCT02832180Phase 1Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Started May 2016
25 enrolled
Arthritis
NCT02691494Phase 3Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Started Feb 2016
378 enrolled
Uterine FibroidsHeavy Menstrual Bleeding
NCT02654054Phase 3Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Started Dec 2015
413 enrolled
Uterine FibroidsHeavy Menstrual Bleeding
NCT01157182Phase 1Completed

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions

Started Feb 2007
36 enrolled
Healthy
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers